Three of the medical device industry's biggest names have a lot riding on the cardiac rhythm management industry. Cardiac powerhouses Boston Scientific (BSX 1.37%) and St. Jude Medical (STJ +0.00%), as well as the market's largest pure medical device maker, Medtronic (MDT +0.25%), all draw a substantial portion of revenue from this hard-hit niche that's seen a slowdown in Europe and heightened rivalry in the industry pressure sales over the past few years. But can these top companies turn around sales losses?
Credit Medtronic for doing its best: This leading device maker has pushed for smaller pacemakers as it looks to inject growth in a sluggish business. Meanwhile, St. Jude and Boston Scientific have celebrated new approvals in this industry from U.S. regulators, but neither saw great performance from CRM revenue in their recent quarterly earnings reports.
Boston Scientific's stock in particular has thrived over the past year despite the ongoing CRM sluggishness, but can these top device picks keep charging higher? Find out in the video below, as Motley Fool contributor Dan Carroll takes you through how these companies rely so much on the CRM industry -- and whether you can count on a turnaround soon in this stumbling business.
